KAI Pharmaceuticals Inc., developer of novel therapeutics for kidney disease, was acquired by Amgen in 2012 for US$315 million.
KAI Pharmaceuticals Inc., developer of novel therapeutics for kidney disease, was acquired by Amgen in 2012 for US$315 million.